News on TLR9 from BioPortfolio.com http://www.BioPortfolio.com Consolidated TLR9 news from BioPortfolio.com Tue, 09 Feb 2010 15:00:46 GMT en Corrigendum to Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primateshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003718&HITNO=0&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003718&THISHREF=http://c.moreover.com/click/here.pl%3fz2519649944%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003718&HITNO=0&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003718&THISHREF=http://c.moreover.com/click/here.pl%3fz2519649944%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMolecular Therapy: Idera Pharmaceuticals Begins Phase 1 Clinical Trial of IMO-3100http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995739&HITNO=1&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995739&THISHREF=http://c.moreover.com/click/here.pl%3fz2515857834%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995739&HITNO=1&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995739&THISHREF=http://c.moreover.com/click/here.pl%3fz2515857834%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Idera Pharmaceuticals initiates Phase I study of autoimmune drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994700&HITNO=2&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994700&THISHREF=http://c.moreover.com/click/here.pl%3fz2515203238%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994700&HITNO=2&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994700&THISHREF=http://c.moreover.com/click/here.pl%3fz2515203238%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Idera Pharmaceuticals initiates Phase I study of autoimmune drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991821&HITNO=3&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991821&THISHREF=http://c.moreover.com/click/here.pl%3fz2513886854%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991821&HITNO=3&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991821&THISHREF=http://c.moreover.com/click/here.pl%3fz2513886854%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended fhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3986576&HITNO=4&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3986576&THISHREF=http://c.moreover.com/click/here.pl%3fz2509256858%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3986576&HITNO=4&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3986576&THISHREF=http://c.moreover.com/click/here.pl%3fz2509256858%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3979469&HITNO=5&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3979469&THISHREF=http://c.moreover.com/click/here.pl%3fz2505777029%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3979469&HITNO=5&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3979469&THISHREF=http://c.moreover.com/click/here.pl%3fz2505777029%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Globe: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended fhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3978410&HITNO=6&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3978410&THISHREF=http://c.moreover.com/click/here.pl%3fz2505263286%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3978410&HITNO=6&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3978410&THISHREF=http://c.moreover.com/click/here.pl%3fz2505263286%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended fhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976476&HITNO=7&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976476&THISHREF=http://c.moreover.com/click/here.pl%3fz2504405598%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976476&HITNO=7&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976476&THISHREF=http://c.moreover.com/click/here.pl%3fz2504405598%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976415&HITNO=8&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976415&THISHREF=http://c.moreover.com/click/here.pl%3fz2504378461%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976415&HITNO=8&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976415&THISHREF=http://c.moreover.com/click/here.pl%3fz2504378461%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976110&HITNO=9&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976110&THISHREF=http://c.moreover.com/click/here.pl%3fz2504264485%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976110&HITNO=9&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976110&THISHREF=http://c.moreover.com/click/here.pl%3fz2504264485%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976086&HITNO=10&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976086&THISHREF=http://c.moreover.com/click/here.pl%3fz2504258744%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976086&HITNO=10&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976086&THISHREF=http://c.moreover.com/click/here.pl%3fz2504258744%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976068&HITNO=11&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976068&THISHREF=http://c.moreover.com/click/here.pl%3fz2504250176%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976068&HITNO=11&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976068&THISHREF=http://c.moreover.com/click/here.pl%3fz2504250176%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-310...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975822&HITNO=12&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975822&THISHREF=http://c.moreover.com/click/here.pl%3fz2504169890%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975822&HITNO=12&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975822&THISHREF=http://c.moreover.com/click/here.pl%3fz2504169890%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975688&HITNO=13&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975688&THISHREF=http://c.moreover.com/click/here.pl%3fz2504129495%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975688&HITNO=13&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975688&THISHREF=http://c.moreover.com/click/here.pl%3fz2504129495%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975638&HITNO=14&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975638&THISHREF=http://c.moreover.com/click/here.pl%3fz2504122764%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975638&HITNO=14&MSIZE=61&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=TLR9&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975638&THISHREF=http://c.moreover.com/click/here.pl%3fz2504122764%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: